---

If you enjoy this content, please share it with a colleague

News | FDA | December 16, 2025

The MyoVista wavECG device is designed to provide conventional ECG functionality while serving as a platform capable of hosting AI-ECG algorithm.

Related Content

Dec. 10, 2025 — HeartBeam, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) ...

December 16, 2025

Oct. 8, 2025 — Viz.ai recently launched Viz ACS, a new solution in the Viz Cardio Suite. Designed to unite the acute ...

October 09, 2025

Aug. 14, 2025 — During HeartBeam, Inc.’s second quarter 2025 earnings conference call, the medical technology company ...

August 15, 2025

July 24, 2025 — Royal Philips has announced a collaboration with Epic to integrate Philips’ suite of cardiac ambulatory ...

July 24, 2025

July 17, 2025 — Royal Philips, a global leader in health technology, has launched the Philips ECG AI Marketplace, a ...

July 17, 2025

July 10, 2025 — A study led by scientists at King’s College London has revealed how the physical orientation of the ...

July 10, 2025

May 8, 2025 – AccurKardia, an innovator in ECG-based diagnostics technology, recently announced that its AccurECG ...

May 19, 2025

November 21, 2023 — AccurKardia, an ECG-led diagnostics software company, announced a multi-year agreement with Lucem ...

November 21, 2023

October 13, 2023 — InfoBionic, Inc. today announced that it received 510(k) clearance from the U.S. Food and Drug ...

October 13, 2023

October 13, 2023 — The newly MDR-certified Cardiomatics solution is accurate, fast and easy-to-use AI-based standalone ...

October 13, 2023